AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02758626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Powder formulation
Study NCT00283166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Education and Coaching
Description: A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
Study NCT00283166 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Education and Coaching
Description: A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
Study NCT02371187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
Study NCT02371187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
Study NCT02730169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules were taken weekly for a maximum of 24 weeks
Study NCT02730169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules were taken weekly for a maximum of 24 weeks
Study NCT00643656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalinox 170 bar
Description: Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
Study NCT00643656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mix of 50% oxygen and 50% nitrogen
Description: Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
Study NCT04501120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.
Study NCT04501120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced-dose HHT
Description: 1mg IV QD on Days 1-14 (28-day cycle).
Study NCT04501120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard-dose HHT
Description: 2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
Study NCT04501120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
Study NCT04501120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily for 14 days, every 28 days as a cycle.
Study NCT00928720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES device
Description: Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Study NCT00928720 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham device
Description: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Study NCT02826785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive strategy training
Description: The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
Study NCT00237159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT03941561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 for 9 months
Description: S-1 for 9 months after D2 resection
Study NCT03941561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 for 1 year
Description: S-1 for 1 year after D2 resection
Study NCT03747237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edema measurement methods
Description: A correlation between the results of the first and second methods will be examined.
Study NCT04031950 — intervention group
Intervention type: DEVICE
Intervention: Novel wearable paediatric device
Description: The patient will wear the novel wearable paediatric device at the same time as polysmnography
Study NCT00738660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan, Ramipril
Description: 80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
Study NCT01767987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
Study NCT01767987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
Study NCT02102945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography perfusion
Description: Computed tomography perfusion of the head
Study NCT06335212 — intervention group
Intervention type: DEVICE
Intervention: Single vision and multifocal contact lenses
Description: Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
Study NCT03005002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03005002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03005002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT02266771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT with Instillation
Description: Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
Study NCT02266771 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NPWT
Description: Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
Study NCT03380273 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation of the AO Trauma SSI Prevention Bundle
Description: AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes
Study NCT03741855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud Dx Kit with self-monitoring
Description: Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
Study NCT03741855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud Dx Kit with remote-monitoring
Description: * Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals.
Study NCT03809533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: 12-week, oral, fixed-dose
Study NCT00263627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
Study NCT04479748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Treatment of pain and inflammation following ophthalmic surgery
Study NCT04479748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Topical steroid
Study NCT01559558 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal packing
Description: vaginal packing after urodynamic studies, and repeat urethral pressure profile
Study NCT01680016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zagreb
Description: Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
Study NCT01680016 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Essen
Description: Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
Study NCT03602027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
Study NCT03602027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg orally daily for three weeks
Study NCT02064140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study NCT00223938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Oral Iron
Study NCT00223938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium ferric gluconate
Description: weekly intravenous injection Dose 1
Study NCT00223938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium ferric gluconate
Description: weekly intravenous injection Dose 2
Study NCT03139721 — intervention group
Intervention type: DEVICE
Intervention: Mosaic model 305, model 310, and ultra model 305
Description: Aortic or mitral valve replacement
Study NCT03235986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)
Description: Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
Study NCT01779375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01779375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Study NCT01268761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Cetrorelix)
Description: •GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
Study NCT01268761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline solution)
Description: • Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
Study NCT01773122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation A
Description: Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
Study NCT03235986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)
Description: Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
Study NCT03235986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
Description: Nasal continuous positive airway pressure alone
Study NCT03235986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)
Description: nasal continuous positive airway pressure alone
Study NCT01688882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
Study NCT01773122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation B
Description: Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
Study NCT01773122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation C
Description: Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
Study NCT01773122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone 5% Gel
Description: Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
Study NCT01688882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used to control for normal variability in disease severity.
Study NCT04316325 — intervention group
Intervention type: DRUG
Intervention: Medical abortion
Description: Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
Study NCT03701126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
Study NCT03701126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
Study NCT03517605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise for cardiac rehabilitation
Description: An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
Study NCT02402647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)
Description: Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET.
Study NCT03970642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy
Description: The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
Study NCT04543825 — intervention group
Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing
Description: Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
Study NCT03059433 — intervention group
Intervention type: OTHER
Intervention: AVID Intervention
Description: Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
Study NCT01066260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Twice a day for 24 days
Study NCT01066260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day for 24 days
Study NCT04449744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MySafeRx Inspire Plus
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
Study NCT04449744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx Inspire Flex
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
Study NCT00903721 — intervention group
Intervention type: DRUG
Intervention: mometasone furoate
Description: Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months
Study NCT04202575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tube clamping
Description: Clamping of the tube between the additional and standard venous reservoir
Study NCT02537899 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NeuroAiD
Study NCT04733300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College for Young Adults
Description: MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs.
Study NCT04733300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education for Young Adults
Description: The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
Study NCT00100178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofeteil (MMF)
Study NCT06745986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided fascia iliaca compartment block ( bupivacaine 0.25% )
Description: Fascia iliaca compartment block by bupivacaine 0.25% in a total volume of 40 ml.
Study NCT06745986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia (bupivacaine)
Description: spinal anesthesia by 2.5 ml bupivacaine 0.5%
Study NCT00100178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB)
Study NCT00100178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control for Mycophenolate mofeteil (MMF)
Description: Placebo pills taken orally
Study NCT00100178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo control for Daclizumab (DZB)
Description: saline intravenous infusions